Top

Published in:

Open Access 01-06-2009 | Review

Targets for active immunotherapy against pediatric solid tumors

Authors: J. F. M. Jacobs, P. G. Coulie, C. G. Figdor, G. J. Adema, I. J. M. de Vries, P. M. Hoogerbrugge

Published in: Cancer Immunology, Immunotherapy | Issue 6/2009

Abstract

The potential role of antibodies and T lymphocytes in the eradication of cancer has been demonstrated in numerous animal models and clinical trials. In the last decennia new strategies have been developed for the use of tumor-specific T cells and antibodies in cancer therapy. Effective anti-tumor immunotherapy requires the identification of suitable target antigens. The expression of tumor-specific antigens has been extensively studied for most types of adult tumors. Pediatric patients should be excellent candidates for immunotherapy since their immune system is more potent and flexible as compared to that of adults. So far, these patients do not benefit enough from the progresses in cancer immunotherapy, and one of the reasons is the paucity of tumor-specific antigens identified on pediatric tumors. In this review we discuss the current status of cancer immunotherapy in children, focusing on the identification of tumor-specific antigens on pediatric solid tumors.

Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882–883PubMed

Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group. Arch Pathol Lab Med 126:540–544PubMed

Amir G, Issakov J, Meller I, Sucher E, Peyser A, Cohen IJ, Yaniv I, Ben Arush MW, Tavori U, Kollender Y, Ron N, Peylan-Ramu N (2002) Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing’s sarcoma: correlation with clinical outcome. Hum Pathol 33:170–174PubMed

Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 177:989–998PubMed

Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C (2006) Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 12:7476–7482PubMed

Ayan I, Dogan O, Kebudi R, Bavbek B, Alatli C, Dervisoglu S, Disci R, Demiryont M (1997) Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome. J Pediatr Hematol Oncol 19:48–53PubMed

Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M (2006) Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55:85–95PubMed

Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, Rutka JT, Squire JA (2000) Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 93:437–448PubMedCrossRef

Biagi E, Bollard C, Rousseau R, Brenner M (2003) Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives. J Biomed Biotechnol 2003:13–24PubMed

10.

Bodey B, Bodey B Jr, Siegel SE (1995) Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors. Mod Pathol 8:333–338PubMed

11.

Bodey B, Siegel SE, Kaiser HE (2002) MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. In Vivo 16:583–588PubMed

12.

Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med 152:1184–1193PubMed

13.

Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337–365PubMed

14.

Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268PubMed

15.

Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208PubMed

16.

Bowman L, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner M (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92:1941–1949PubMed

17.

Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121–1124PubMed

18.

Browett PJ, Cooke HM, Secker-Walker LM, Norton JD (1989) Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet 37:169–177PubMed

19.

Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, Downie P, Hassall TE, Tang ML, Ashley DM (2004) Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 6:236–246PubMed

20.

Cheung IY, Cheung NK (1997) Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 3:821–826PubMed

21.

Cheung IY, Cheung NK (2001) Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol 36:210–212PubMed

22.

Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143–2152PubMed

23.

Cooper LJ (2008) Adoptive cellular immunotherapy for childhood malignancies. Bone Marrow Transplant 41:183–192PubMed

24.

Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169:1829–1836PubMed

25.

Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V (1996) Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer 69:403–407PubMed

26.

Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL (2002) Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38:158–164PubMed

27.

Dalerba P, Frascella E, Macino B, Mandruzzato S, Zambon A, Rosolen A, Carli M, Ninfo V, Zanovello P (2001) MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int J Cancer 93:85–90PubMed

28.

de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M (2000) Prognostic impact of P53 status in Ewing sarcoma. Cancer 89:783–792PubMed

29.

De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R, Van Gool SW (2004) Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100:492–497PubMed

30.

De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098–3104PubMed

31.

Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162–165PubMed

32.

Dennis SL, Manji SS, Carrington DP, Scarcella DL, Ashley DM, Smith PJ, Algar EM (2002) Expression and mutation analysis of the Wilms’ tumor 1 gene in human neural tumors. Int J Cancer 97:713–715PubMed

33.

Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J (1994) MYCN gene amplification in rhabdomyosarcoma. Cancer 73:2231–2237PubMed

34.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998PubMed

35.

Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW (2002) Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 188:136–146PubMed

36.

Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681–1691PubMed

37.

Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630–641PubMed

38.

Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117PubMed

39.

Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835–837PubMed

40.

Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children’s Cancer Group. Cancer 80:317–333PubMed

41.

Gambini C, Sementa AR, Boni L, Marino CE, Croce M, Negri F, Pistoia V, Ferrini S, Corrias MV (2003) Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. Cancer Immunol Immunother 52:116–120PubMed

42.

Gandhi MK, Tellam JT, Khanna R (2004) Epstein-Barr virus-associated Hodgkin’s lymphoma. Br J Haematol 125:267–281PubMed

43.

Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513–8519PubMed

44.

Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J (1997) Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57:3272–3280PubMed

45.

Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J (1996) c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer 73:620–623PubMed

46.

Hachitanda Y, Toyoshima S, Akazawa K, Tsuneyoshi M (1998) N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol 11:1222–1227PubMed

47.

Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM (2000) Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265–276PubMed

48.

Himoudi N, Yan M, Papanastasiou A, Anderson J (2008) MYCN as a target for cancer immunotherapy. Cancer Immunol Immunother 57:693–700PubMed

49.

Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT (2004) Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64:2047–2053PubMed

50.

Hui AB, Lo KW, Yin XL, Poon WS, Ng HK (2001) Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 81:717–723PubMedCrossRef

51.

Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–2368PubMed

52.

Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T (1996) MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 69:375–380PubMed

53.

Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T (2005) Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 28:565–568PubMed

54.

Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ, Hoogerbrugge PM, Coulie PG, de Vries IJ (2007) Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120:67–74PubMed

55.

Jacobs JF, Hoogerbrugge PM, de Rakt MW, Aarntzen EH, Figdor CG, Adema GJ, de Vries IJ (2007) Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatr Blood Cancer 49:924–927PubMed

56.

Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 58(1):145–151. doi:10.1007/s00262-008-0506-5 PubMed

57.

Jacobs JF, Grauer OM, Brasseur F, Hoogerbrugge PM, Wesseling P, Gidding CE, van de Rakt MW, Figdor CG, Coulie PG, de Vries IJ, Adema GJ (2008) Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol 88(3):273–280PubMed

58.

Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66:373–385PubMed

59.

Joshi BH, Leland P, Puri RK (2003) Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein. Croat Med J 44:455–462PubMed

60.

Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97:1077–1083PubMed

61.

Kalos M (2003) Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 21:781–786PubMed

62.

Kalwak K, Ussowicz M, Gorczynska E, Turkiewicz D, Toporski J, Dobaczewski G, Latos-Grazynska E, Ryczan R, Noworolska-Sauren D, Chybicka A (2003) Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors. J Interferon Cytokine Res 23:173–181PubMed

63.

Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, Connerotte T, Corbiere V, Demoitie MA, Lienard D, Dreno B, Velu T, Boon T, Coulie PG (2003) Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171:4898–4904PubMed

64.

Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY (2003) Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 64:71–76PubMed

65.

Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK (2004) Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101:1036–1042PubMed

66.

Kershaw MH, Trapani JA, Smyth MJ (1995) Cytotoxic lymphocytes redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 2:173–181PubMed

67.

Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS (1999) cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 96:13264–13269PubMed

68.

Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 33:261–266PubMed

69.

Korshunov A, Golanov A, Timirgaz V (2002) Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 58:255–270PubMed

70.

Kuroki M, Shibaguchi H, Imakiire T, Uno K, Shirota K, Higuchi T, Shitama T, Yamada H, Hirose Y, Nagata A (2003) Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res 23:4377–4381PubMed

71.

Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482–5493PubMed

72.

Lampson LA (2003) Brain tumor immunotherapy: an immunologist’s perspective. J Neurooncol 64:3–11PubMed

73.

Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9:949–954PubMed

74.

Larin SS, Georgiev GP, Kiselev SL (2004) Gene transfer approaches in cancer immunotherapy. Gene Ther 11(Suppl 1):S18–S25PubMed

75.

Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, Razzouk BI, Mathew P, Shearer P, Evans WE, Pui CH (2000) Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 18:3273–3279PubMed

76.

Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS (1999) Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 91:1051–1058PubMed

77.

Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980–4986PubMed

78.

Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329–339PubMed

79.

Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA (2000) Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol 35:641–646PubMed

80.

Lu S, Wang S, Grimes-Serrano JM (2008) Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 7:175–191PubMed

81.

Mackall C, Berzofsky J, Helman LJ (2000) Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop Relat Res 373:25–31PubMed

82.

Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14:4850–4858PubMed

83.

Mark HF, Brown S, Sun CL, Samy M, Afify A (1998) Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 66:59–63PubMed

84.

Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057PubMed

85.

Miralbell R, Tolnay M, Bieri S, Probst A, Sappino AP, Berchtold W, Pepper MS, Pizzolato G (1999) Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neurooncol 45:103–110PubMed

86.

Modak S, Cheung NK (2005) Antibody-based targeted radiation to pediatric tumors. J Nucl Med 46(Suppl 1):157S–163SPubMed

87.

Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67–77PubMed

88.

Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS (1994) Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184–193PubMed

89.

Nakachi K, Hayashi T, Imai K, Kusunoki Y (2004) Perspectives on cancer immuno-epidemiology. Cancer Sci 95:921–929PubMed

90.

Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207PubMed

91.

Oda Y, Wehrmann B, Radig K, Walter H, Rose I, Neumann W, Roessner A (1995) Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 141:97–103PubMed

92.

Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF (2008) Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 88(3):245–250PubMed

93.

Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693–702PubMed

94.

Parney IF, Chang LJ (2003) Cancer immunogene therapy: a review. J Biomed Sci 10:37–43PubMed

95.

Pavlenko M, Leder C, Pisa P (2005) Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Expert Rev Vaccines 4:315–327PubMed

96.

Penn I (1988) Tumors of the immunocompromised patient. Annu Rev Med 39:63–73PubMed

97.

Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA (2003) Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101:649–654PubMed

98.

Porter DL, Antin JH (1999) The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50:369–386PubMed

99.

Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3:569–581PubMed

100.

Rickert CH, Strater R, Kaatsch P, Wassmann H, Jurgens H, Dockhorn-Dworniczak B, Paulus W (2001) Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 158:1525–1532PubMed

101.

Ridgway D (2003) The first 1000 dendritic cell vaccinees. Cancer Invest 21:873–886PubMed

102.

Rimoldi D, Romero P, Carrel S (1993) The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 54:527–528PubMed

103.

Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G (1992) Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 34:241–251PubMed

104.

Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C (2003) Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 63:6948–6955PubMed

105.

Rowlinson-Busza G, Epenetos AA (1992) Targeted delivery of biologic and other antineoplastic agents. Curr Opin Oncol 4:1142–1148PubMed

106.

Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A (2005) Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 17:211–217PubMed

107.

Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R (2007) Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 30:227–233PubMed

108.

Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W, Pfreundschuh M (2000) Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6:3916–3922PubMed

109.

Sasaki T, Lopes MB, Hankins GR, Helm GA (2002) Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol (Berl) 104:105–109

110.

Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM (1999) Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5:335–341PubMed

111.

Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H, Hofler H (1994) Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol 25:772–780PubMed

112.

Seibel NL, Dinndorf PA, Bauer M, Sondel PM, Hammond GD, Reaman GH (1994) Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children’s Cancer Group study. J Immunother Emphasis Tumor Immunol 16:125–131PubMed

113.

Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M (2006) Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97:807–812PubMed

114.

Serraino D, Piselli P, Angeletti C, Scuderi M, Ippolito G, Capobianchi MR (2005) Infection with Epstein-Barr virus and cancer: an epidemiological review. J Biol Regul Homeost Agents 19:63–70PubMed

115.

Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615–625PubMed

116.

Sinkovics JG, Horvath JC (2000) Vaccination against human cancers (review). Int J Oncol 16:81–96PubMed

117.

Soling A, Schurr P, Berthold F (1999) Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 19:2205–2209PubMed

118.

Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K (1997) Expression of MAGE genes in osteosarcoma. J Orthop Res 15:128–132PubMed

119.

Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137–1146PubMed

120.

Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R (2003) Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. Clin Neuropathol 22:180–186PubMed

121.

Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol 17:660–669PubMed

122.

Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR (2003) Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 29:379–382PubMed

123.

Truitt RL, Piaskowski V, Kirchner P, McOlash L, Camitta BM, Casper JT (1992) Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. J Immunother 11:274–285PubMed

124.

Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, Hameed M (2004) HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 22:16–24PubMed

125.

Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N (2006) Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8–5. Cancer Sci 97:1374–1380PubMed

126.

Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J (2001) p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 158:2067–2077PubMed

127.

Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN (2006) Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 90:215–241PubMed

128.

Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL (1995) Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother 41:29–36PubMed

129.

van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA (2006) Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 66:1818–1823PubMed

130.

van Noesel MM, Versteeg R (2004) Pediatric neuroblastomas: genetic and epigenetic ‘danse macabre’. Gene 325:1–15PubMed

131.

Velders MP, Markiewicz MA, Eiben GL, Kast WM (2003) CD4+ T cell matters in tumor immunity. Int Rev Immunol 22:113–140PubMed

132.

Vital A, Loiseau H, Kantor G, Daucourt V, Chene G, Cohadon F, Rougier A, Rivel J, Vital C (1998) p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathol Res Pract 194:831–836PubMed

133.

Vlk V, Eckschlager T, Kavan P, Kabickova E, Koutecky J, Sobota V, Bubenik J, Pospisilova D (2000) Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients. Pediatr Hematol Oncol 17:31–44PubMed

134.

Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, Todryk S (2002) Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 51:351–357PubMed

135.

Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS (1998) Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 16:536–544PubMed

136.

Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101:2290–2296PubMed

137.

Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 102:455–462PubMed

138.

Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y (1999) Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 54:153–161PubMed

139.

Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE (2003) Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25:27–32PubMed

Title: Targets for active immunotherapy against pediatric solid tumors
Authors: J. F. M. Jacobs
P. G. Coulie
C. G. Figdor
G. J. Adema
I. J. M. de Vries
P. M. Hoogerbrugge
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0619-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells

Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo

Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer